Company: LBRX
Filing Date: 2025-08-22
Form Type: S-1
Source: 0001193125-25-186467
Chunk: 270

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-08-22
Form: S-1
Chunk 270
---
000 |     |               |   500,000 | -2 |     |          | 1.50 |     |            | 08/28/2033 |     |                 | — |     |          | — |
|                    |     |            | 06/28/2024 |     |                  |       — |     |               |   175,000 | -2 |     |          | 1.50 |     |            | 06/27/2034 |     |                 | — |     |          | — |

| (1) | The equity awards listed in the table above were granted under the 2023 Plan, the 2018 Plan, and the 2017 Plan. |

| (2) | 25% of the option vests upon the first anniversary of the grant date, and the remainder vests and becomes 
 exercisable in thirty-six (36) substantially equal monthly installments thereafter.                       |

| (3) | Resigned as our Chief Executive Officer in connection with Ms. Turner’s appointment as Chief Executive                                                                                                   
 Officer. In connection with such resignation, Mr. Prensky’s outstanding option awards were treated as described below under “—Potential Payments Upon Termination or Change in Control—Zachary Prensky.” |

| (4) | Was terminated from the Chief Financial Officer role in May 2025. In connection with such termination,                                                 
 Mr. Sawhney’s outstanding option award was treated as described below under “—Potential Payments Upon Termination or Change in Control—Roger Sawhney.” |

Employment Arrangements We are party to employment agreements with each of our named executive officers. The employment agreements set forth the named executive officer’s base salary, eligibility for employee benefits, and severance benefits upon a qualifying termination of employment or change in control of our Company and, other than Ms. Turner, generally provide for an initial term commencing on the effective date of the applicable agreement and ending on the one-yearanniversary of the effective date. After the initial one-yearterm, the employment agreement will automatically renew for successive one-yearterms. Either we or the executive may elect not to renew the employment agreement after the initial one-yearterm by providing the other party written notice of non-renewalnot less than ninety (90) days prior to the expiration of the then-existing employment period. Each of our named executive officers has executed our standard confidential information, inventions assignment, and arbitration agreement. The key terms of the employment